WO 2010/083148 Al

Total Page:16

File Type:pdf, Size:1020Kb

WO 2010/083148 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 July 2010 (22.07.2010) WO 2010/083148 Al (51) International Patent Classification: (74) Agents: GAO, Chuan et al.; Townsend and Townsend Cl 2P 21/00 (2006.01) and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, California 941 11 (US). (21) International Application Number: PCT/US20 10/020727 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, 12 January 2010 (12.01 .2010) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (26) Publication Language: English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (30) Priority Data: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 61/144,401 13 January 2009 (13.01 .2009) US NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (71) Applicant (for all designated States except US): SUTRO TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. BIOPHARMA, INC. [US/US]; 310 Utah Street, Suite 150, South San Francisco, California 94080 (US). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (72) Inventors; and GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (75) Inventors/Applicants (for US only): VOLOSHIN, Alex- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, ei M. [US/US]; 3717 1 Sycamore Street, Apt. 137, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Newark, California 94560 (US). ZAWADA, James F. ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, [US/US]; 720 Upton Street, Redwood City, California MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, 9406 1 (US). GOLD, Daniel [US/US]; 3223 Santiago TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Street, San Francisco, California 941 16 (US). ML, MR, NE, SN, TD, TG). [Continued on next page] (54) Title: USE OF DNA GYRASE INHIBITORS FOR IN VITRO POLYPEPTIDE SYNTHESIS REACTIONS (57) Abstract: The present invention provides methods and compositions u se ful for in vitro polypeptide synthesis re Addition of Ciprofloxacin during lysate preparation does not actions. The methods involve the use of impact GM-CSF yields DNA gyrase inhibitors to prevent bacte rial contamination in lysates used for in vitro production of polypeptides. The compositions include contamination-free cell lysates for in vitro protein synthesis reactions. Total E2 Soluble Control Cipro 1µg/mL FIG. 1 Published: USE OF DNA GYRASE INHIBITORS FOR IN VITRO POLYPEPTIDE SYNTHESIS REACTIONS RELATED APPLICATIONS [0001] This application claims priority to U.S. Provisional Patent Application No. 61/144,401, filed January 13, 2009, the contents of which are incorporated by reference in the entirety for all purposes. FIELD OF THE INVENTION [0002] This invention relates to in vitro polypeptide synthesis. In particular, the invention relates to methods of using antibiotics that are DNA gyrase inhibitors during the in vitro polypeptide synthesis. The invention also provides compositions that are lysates containing DNA gyrase inhibitors for in vitro polypeptide synthesis reactions. The use of DNA gyrase inhibitors during in vitro polypeptide synthesis reactions enhances output of the desired protein. The present invention is particularly useful in an in vitro or cell-free system where protein synthesis is directed by the T7 bacteriophage promoter. BACKGROUND OF THE INVENTION [0003] Protein synthesis is a fundamental biological process that underlies the development of polypeptide therapeutics, vaccines, diagnostics, and industrial enzymes. With the advent of recombinant DNA (rDNA) technology, it has become possible to harness the catalytic machinery of the cell to produce a desired protein. This can be achieved within the cellular environment or in vitro using lysates derived from cells. [0004] In vitro, or cell-free, protein synthesis offers several advantages over conventional in vivo protein expression methods. Cell-free systems can direct most, if not all, of the metabolic resources of the cell towards the exclusive production of one protein. Moreover, the lack of a cell wall and membrane components in vitro is advantageous because it allows for control of the synthesis environment. For example, tRNA levels can be changed to reflect the codon usage of genes being expressed. The redox potential, pH, or ionic strength can also be altered with greater flexibility than with in vivo protein synthesis because concerns of cell growth or viability do not exist. Furthermore, direct recovery of purified, properly folded protein products can be easily achieved. [0005] The productivity of cell-free systems has improved over two orders of magnitude in recent years, from about 5µg/ml-hr to about 150, 250, or 500µg/ml-hr. Such improvement has made in vitro protein synthesis a practical technique for laboratory-scale research and provided a platform technology for high-throughput protein expression. It further indicates the feasibility for using cell-free technologies as an alternative means to in vivo large-scale commercial production of protein pharmaceuticals. [0006] The productivity of in vitro polypeptide synthesis systems can be significantly hindered by bacterial contamination. While many commercially available antibiotics exist for use to inhibit bacterial growth that occurs within an in vitro reaction lysate, most of these antibiotics interfere with protein synthesis or are not acceptable for production of pharmaceuticals. There exists a need for antibiotic application for eliminating bacterial growth in an in vitro polypeptide synthesis reaction lysate without interfering with the in vitro protein synthesis reaction, such that the output of the desired polypeptide is permitted and/or enhanced. The invention described herein fulfills these needs, as will be apparent upon review of the following disclosure. BRIEF SUMMARY OF THE INVENTION [0007] In one aspect, this invention provides a method for in vitro synthesis of a polypeptide. The method includes the step of adding at least one DNA gyrase inhibitor to a polypeptide synthesis reaction lysate in an amount sufficient to inhibit bacterial growth, especially in a reaction lysate where the polypeptide is synthesized from an expression cassette comprising a polynucleotide sequence encoding the polypeptide, where the coding sequence is operably linked to a T7 promoter. The DNA gyrase inhibitor may be a quinolone or an aminocoumarin. [0008] In some embodiments, ciprofloxacin, one of the quinolones, is used in the methods of the present invention. In other embodiments, another quinolone, norfloxacin, is used. Other quinolones useful in the methods of this invention include cinoxacin, flumequine, nalidixic acid, oxolinic acid, piromidic acid, pipemidic acid, rosoxacin, enoxacin, fleroxacin, iomefloxacin, nadifloxacin, ofloxacin, pefloxacin, rufloxacin, balofloxacin, gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin, pazufloxacin, sparfloxacin, temafloxacin, tosufloxacin, clinafloxacin, garenoxacin, gemifloxacin, sitafloxacin, trovafloxacin, prolifloxacin, and ecinofloxacin. [0009] In some embodiments, coumermycin A 1, one of the aminocoumarins, is used in the methods of the present invention. In other embodiments, another aminocoumarin, novobiocin, is used. Clorobiocin is an additional aminocoumarin that may be useful in the cell-free protein synthesis method of this invention. Any combination of two or more of quinolones and/or aminocoumarins, such as those named above, can be used in the method of this invention. [0010] The method of the present invention may be used to suppress the growth of either facilitative anaerobic microorganisms or aerobic microorganisms. [0011] In a second aspect, the present invention provides an in vitro polypeptide synthesis reaction lysate or mixture, which contains at least one DNA gyrase inhibitor in an amount sufficient to inhibit bacterial growth. In particular, this reaction mixture contains an expression cassette that includes a polynucleotide sequence encoding a polypeptide to be synthesized, operably linked to a T7 promoter. The DNA gyrase inhibitor may be a quinolone or an aminocoumarin. [0012] In some embodiments, ciprofloxacin, one of the quinolones, is used in the reaction mixtures of the present invention. In other embodiments, another quinolone, norfloxacin, is used. Other quinolones useful in the reaction mixtures of this invention include cinoxacin, flumequine, nalidixic acid, oxolinic acid, piromidic acid, pipemidic acid, rosoxacin, enoxacin, fleroxacin, iomefloxacin, nadifloxacin, ofloxacin, pefloxacin, rufloxacin, balofloxacin, gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin, pazufloxacin, sparfloxacin, temafloxacin, tosufloxacin, clinafloxacin, garenoxacin, gemifloxacin, sitafloxacin, trovafloxacin, prolifloxacin, and ecinofloxacin. [0013] In some embodiments, coumermycin A 1, one of the aminocoumarins, is used in the reaction mixtures of the present invention. In other embodiments, another aminocoumarin, novobiocin, is used. Clorobiocin is an additional aminocoumarin that may be useful in the cell-free protein synthesis reaction lysate of this invention. Any combination of
Recommended publications
  • A Review on the Current Classification and Regulatory Provisions for Medicines in Drug & Cosmetic Act, in the Light of Present Day Context
    Section Pharmaindustry Commentary A Review on the Current Classification and Regulatory Provisions for Medicines in Drug & Cosmetic Act, in the light of Present Day Context Prashant Tandon1, Varun Gupta2, Ashish Ranjan3, Purav Gandhi4, Anand Kotiyal5, 3 Aastha Kapoor 3 1Founder ;2VP & Head Medical Affair; Manager Medical Affair; 5Drug Data Analyst Medical Affair, 1mg Technologies Private Limited, 4th Floor, Motorola Building, MG Road, Sector 14, Gurugram, Haryana, 122001. 4Founder, Remedy Social, C/602, Tulip Citadel, Shreyas Tekra, Ambawadi, Ahmedabad 380015, Gujarat. ABSTRACT______________________________________________________________ Background: Current classification of medicines in Conclusions: We have recommended a revised drug India under Drug and Cosmetic Act into Schedule G, classification system that is more comprehensive in coverage and H, H1, X is outdated, evolved through patchwork over eliminates the overlaps between classes. Moreover, considering the years and needs to be thoroughly updated. The the implementation challenges for such a drug classification primary aim of the scheduling system is to ensure system in the diverse and fragmented ecosystem in India, we appropriate access to medicines while balancing recommend a technology backed platform to help monitor the public health and safety. India is experiencing a rapid implementation. transition with the rising burden of chronic non- communicable diseases where regular access of Key words: Drug Classification System, Drug and Cosmetic Act affordable medicines is critical for chronic disease India, Digitization of Prescriptions, Drug Schedules in India, management to prevent complications. Methods: We Schedule H, Monitoring Drug Schedule System analyzed drugs commonly selling across India, Received: 01.09.17 | Accepted:16.09.17 through multiple information sources including 1mg drug database, PharmaTrac (AIOCD-AWACS), Corresponding Author inventory data from distributors and retailers, Dr.
    [Show full text]
  • 1057-1064, 1984 the Effect of Pipemidic Acid on The
    Microbiol. Immunol. Vol. 28 (9), 1057-1064, 1984 The Effect of Pipemidic Acid on the Growth of a Stable L-Form of •ôNH•ôStaphylococcus aureus•ôNS•ô Kunihiko YABU,*,1 Hiromi ToMizu,1 and Yayoi KANDA2 1 Department of Biology, Hokuriku University School of Pharmacy, Kanazawa-machi, Kanazawa, Ishikawa ,920-11, and 2Department of Microbiology, Teikyo University School of Medicine, Kaga 2-chome, Ilabashi-ku, Tokyo 173 (Accepted for publication, June 12, 1984) Bacterial L-forms usually display spherical forms in an osmotically protective medium and seem to lack the typical binary fission process of cellular division ob servedin most bacteria (7). Although various modes of replication, such as budding binary fission, and release of elementary bodies from large bodies have been observed by light and electron microscopy (2, 5, 16), little is known about the processes involved in replication of L-forms. In the course of an experiment designed to test the effect of DNA synthesis inhibitors on the growth of a stable L-form of •ôNH•ôStaphylococcus•ôNS•ôaureus which grows in liquid medium, it was found that pipemidic acid, a synthetic antibacterial agent structurally related to nalidixic acid (13), induced a marked morphological altera tionat growth inhibitory concentrations. This study was initiated in an attempt to clarify the mechanism of replication of stable L-forms by analyzing the mor phologicalalteration caused by pipemidic acid. The stable L-form used was isolated as follows. S. •ôNH•ôaureus•ôNS•ôFDA 209P was grown in 10ml of Brain Heart Infusion broth (Difco) at 37C. The culture grown at 5•~105 colony-forming units (CFU) per ml was washed with saline by filtration and suspended in saline containing 100ƒÊg of N-methyl-N'-nitro-N-nitrosoguanidine per nil.
    [Show full text]
  • Clinically Isolated Chlamydia Trachomatis Strains
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUIY 1988, p. 1080-1081 Vol. 32, No. 7 0066-4804/88/071080-02$02.00/0 Copyright © 1988, American Society for Microbiology In Vitro Activities of T-3262, NY-198, Fleroxacin (AM-833; RO 23-6240), and Other New Quinolone Agents against Clinically Isolated Chlamydia trachomatis Strains HIROSHI MAEDA,* AKIRA FUJII, KATSUHISA NAKATA, SOICHI ARAKAWA, AND SADAO KAMIDONO Department of Urology, School of Medicine, Kobe University, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe-city, Japan Received 9 December 1987/Accepted 29 March 1988 The in vitro activities of three newly developed quinolone drugs (T-3262, NY-198, and fleroxacin [AM-833; RO 23-6240]) against 10 strains of clinically isolated Chiamydia trachomatis were assessed and compared with those of other quinolones and minocycline. T-3262 (MIC for 90% of isolates tested, 0.1 ,ug/ml) was the most active of the quinolones. The NY-198 and fleroxacin MICs for 90% of isolates were 3.13 and 62.5 ,ug/ml, respectively. Recently, it has become well known that Chlamydia 1-ml sample of suspension was seeded into flat-bottomed trachomatis is an important human pathogen. It is respon- tubes with glass cover slips and incubated at 37°C in 5% CO2 sible not only for trachoma but also for sexually transmitted for 24 h. The monolayer was inoculated with 103 inclusion- infections, including lymphogranuloma venereum. In forming units of C. trachomatis. The tubes were centrifuged women, it causes cervicitis, endometritis, and salpingitis at 2,000 x g at 25°C for 45 min and left undisturbed at room asymptomatically (19), while in men it causes nongono- temperature for 2 h.
    [Show full text]
  • Repurposing Drug Scaffolds: a Tool for Developing Novel Therapeutics with Applications in Malaria and Lung Cancer
    Repurposing Drug Scaffolds: A Tool for Developing Novel Therapeutics with Applications in Malaria and Lung Cancer A Thesis Submitted by: Hannah Elizabeth Cook In partial fulfilment of the requirements for the degree of: Doctor of Philosophy September 2018 Supervisors: Professor Matthew J. Fuchter & Professor Anthony G. M. Barrett Department of Chemistry Imperial College London 2 Declaration of Originality I, Hannah Cook, hereby confirm that the work presented within this thesis is entirely my own, conducted under the supervision of Professor Matthew J. Fuchter and Professor Anthony G. M. Barrett, at the Department of Chemistry, Imperial College London, unless otherwise stated. All work performed by others has been acknowledged within the text and referenced where appropriate. Hannah E. Cook September 2018 Copyright Declaration The copyright of this thesis rests with the author and is made available under a Creative Commons Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, distribute or transmit the thesis on the condition that they attribute it, that they do not use it for commercial purposes and that they do not alter, transform or build upon it. For any reuse or redistribution, researchers must make clear to others the licence terms of this work. 3 Abstract The definition of repurposing in the context of drug discovery encompasses a variety of strategies designed to redirect current therapeutic knowledge towards new disease indications. This approach can be successful for the design of new drugs to treat diseases of the developing world such as Malaria, where there are limited resources to fund new drug discovery campaigns. Moreover, it can be used to decrease the drug development time for diseases in which there is high drug attrition rates coupled with high mortality rates, which is the case for some cancers.
    [Show full text]
  • Dissertation
    DISSERTATION FOLATE PATHWAY INHIBITOR RESISTANCE MECHANISMS IN BURKHOLDERIA PSEUDOMALLEI Submitted by Nicole L. Podnecky Department of Microbiology, Immunology and Pathology In partial fulfillment of the requirements For the Degree of Doctor of Philosophy Colorado State University Fort Collins, Colorado Fall 2013 Doctoral Committee: Advisor: Herbert P. Schweizer Steven W. Dow Richard A. Slayden Laurie A. Stargell ABSTRACT FOLATE PATHWAY INHIBITOR RESISTANCE MECHANISMS IN BURKHOLDERIA PSEUDOMALLEI Antimicrobials are invaluable tools used to facilitate the treatment of infectious diseases. Their use has saved millions of lives since their introduction in the early 1900’s. Unfortunately, due to the increased incidence and dispersal of antimicrobial resistance determinants, many of these drugs are no longer efficacious. This greatly limits the options available for treatment of serious bacterial infections, including melioidosis, which is caused by Burkholderia pseudomallei, a Gram-negative saprophyte. This organism is intrinsically resistant to many antimicrobials. Additionally, there have been reports of B. pseudomallei isolates resistant to several of the antimicrobials currently used for treatment, including the trimethoprim and sulfamethoxazole combination, co-trimoxazole. The overarching goal of this project was to identify and characterize mechanisms of trimethoprim and sulfamethoxazole resistance in clinical and environmental isolates, as well as in laboratory induced mutants. Prior to these studies, very little work has been done to identify and characterize the mechanisms by which B. pseudomallei strains are or could become resistant to folate-pathway inhibitors, specifically trimethoprim and sulfamethoxazole. During the initial phases of these studies, we determined the antimicrobial susceptibilities of a large collection of clinical and environmental isolates from Thailand and Australia (n = 65).
    [Show full text]
  • A TWO-YEAR RETROSPECTIVE ANALYSIS of ADVERSE DRUG REACTIONS with 5PSQ-031 FLUOROQUINOLONE and QUINOLONE ANTIBIOTICS 24Th Congress Of
    A TWO-YEAR RETROSPECTIVE ANALYSIS OF ADVERSE DRUG REACTIONS WITH 5PSQ-031 FLUOROQUINOLONE AND QUINOLONE ANTIBIOTICS 24th Congress of V. Borsi1, M. Del Lungo2, L. Giovannetti1, M.G. Lai1, M. Parrilli1 1 Azienda USL Toscana Centro, Pharmacovigilance Centre, Florence, Italy 2 Dept. of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), 27-29 March 2019 Section of Pharmacology and Toxicology , University of Florence, Italy BACKGROUND PURPOSE On 9 February 2017, the Pharmacovigilance Risk Assessment Committee (PRAC) initiated a review1 of disabling To review the adverse drugs and potentially long-lasting side effects reported with systemic and inhaled quinolone and fluoroquinolone reactions (ADRs) of antibiotics at the request of the German medicines authority (BfArM) following reports of long-lasting side effects systemic and inhaled in the national safety database and the published literature. fluoroquinolone and quinolone antibiotics that MATERIAL AND METHODS involved peripheral and central nervous system, Retrospective analysis of ADRs reported in our APVD involving ciprofloxacin, flumequine, levofloxacin, tendons, muscles and joints lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin, prulifloxacin, rufloxacin, cinoxacin, nalidixic acid, reported from our pipemidic given systemically (by mouth or injection). The period considered is September 2016 to September Pharmacovigilance 2018. Department (PVD). RESULTS 22 ADRs were reported in our PVD involving fluoroquinolone and quinolone antibiotics in the period considered and that affected peripheral or central nervous system, tendons, muscles and joints. The mean patient age was 67,3 years (range: 17-92 years). 63,7% of the ADRs reported were serious, of which 22,7% caused hospitalization and 4,5% caused persistent/severe disability. 81,8% of the ADRs were reported by a healthcare professional (physician, pharmacist or other) and 18,2% by patient or a non-healthcare professional.
    [Show full text]
  • Nigerian Veterinary Journal 39(3)
    Nigerian Veterinary Journal 39(3). 2018 Asambe et al. NIGERIAN VETERINARY JOURNAL ISSN 0331-3026 Nig. Vet. J., September 2018 Vol 39 (3): 199 -208. https://dx.doi.org/10.4314/nvj.v39i3.3 ORIGINAL ARTICLE In Vitro Comparative Activity of Ciprofloxacin and Enrofloxacin against Clinical Isolates from Chickens in Benue State, Nigeria Asambe, A.1*; Babashani, M2. and Salisu, U. S.1 ¹.Federal University Dutsinma, Katsina State. 2.Ahmadu Bello University Zaria. *Corresponding author: Email: [email protected]; Tel No:+2348063103254 SUMMARY This study compares the in vitro activities of enrofloxacin and its main metabolite ciprofloxacin against clinical Escherichia coli and non-lactose fermenting enterobacteria isolates from chickens. Ten (10) Escherichia coli and 8 non lactose fermenting enterobacteriaceae species isolated from a pool of clinical cases at the Microbiology Laboratory of the Veterinary Teaching Hospital, University of Agriculture Makurdi were used in this study. Ten-fold serial dilution of 10 varying concentrations (0.1-50μg/mL) of enrofloxacin and ciprofloxacin were tested against the isolates in vitro by Bauer’s disc-diffusion method to determine and compare their antimicrobial activities against the isolates. The 18 isolates tested were susceptible to both enrofloxacin and ciprofloxacin, and their mean values in the susceptibility of Escherichia coli and non-lactose fermenters were significantly different (p < 0.01). The study concluded that the clinical isolates are susceptible to both enrofloxacin and ciprofloxacin though ciprofloxacin exhibit higher activity. Comparatively, ciprofloxacin was found to be more potent than enrofloxacin and the difference statistically significant. Ciprofloxacin was recommended as a better choice in the treatment of bacterial infections of chicken in this area compared to enrofloxacin.
    [Show full text]
  • The Effect of Chloramphenicol on BB88 Murine Erythroleukemia Cells
    Western Michigan University ScholarWorks at WMU Dissertations Graduate College 8-2007 The Effect of Chloramphenicol on BB88 Murine Erythroleukemia Cells Peter K. W. Harris Western Michigan University Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Chemistry Commons Recommended Citation Harris, Peter K. W., "The Effect of Chloramphenicol on BB88 Murine Erythroleukemia Cells" (2007). Dissertations. 872. https://scholarworks.wmich.edu/dissertations/872 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. THE EFFECT OF CHLORAMPHENICOL ON BB88 MURINE ERYTHROLEUKEMIA CELLS by Peter K. W. Harris A Dissertation Submitted to the Faculty o f The Graduate College in partial fulfillment of the requirements for the Degree of Doctor of Philosophy Department of Biological Sciences Western Michigan University Kalamazoo, Michigan August 2007 Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. THE EFFECT OF CHLORAMPHENICOL ON BB88 MURINE ERYTHROLEUKEMIA CELLS Peter K. W. Harris, Ph.D. Western Michigan University, 2007 DNA microarrays can be used to measure genome-wide transcript levels. These measurements may be useful in understanding cellular changes induced by a chemical agent. In this study, Affymetrix microarray technology has been used to study the effects of chloramphenicol, an antibiotic that inhibits bacterial and mitochondrial protein synthesis, on the transcription profile in mammalian cells. Transcript levels in BB88 murine erythroleukemia cells treated with 50 micromolar (pM) chloramphenicol, a concentration shown to inhibit BB 88 proliferation, are measured.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Molecular and Immunological Sd0100025 Characterization of Mycobacteria Associated with Bovine Farcy
    MOLECULAR AND IMMUNOLOGICAL SD0100025 CHARACTERIZATION OF MYCOBACTERIA ASSOCIATED WITH BOVINE FARCY. Thesis submitted in accordance with requirements of the University of Khartoum for the Degree of Doctor of Philosophy (Ph.D). By Victor Loku Kwajok B.V.Med. 1978, University of Cairo/Egypt. M.V.Sc.1992, University of Khartoum/Sudan. Supervisor: Dr. Maowia M. Mukhtar. Institute of Endemic Diseases, University of Khartoum. Department of Preventive Medicine and Veterinary Public Health. Faculty of Veterinary Science, University of Khartoum. 2000. 32/27 SOME PAGES ARE MISSING IN THE ORIGINAL DOCUMENT LIST OF CONTENTS DEDICATION. * ii v ACKNOWLEDGEMENTS vi ABBREVIATIONS viii ABSTRACT. xi CHAPTER ONE. REVIEW OF LITERATURE. 1. General Introduction. 1. 1.1. Molecular Systematics of genus Mycobacterium. 2. 1.2. Molecular taxonomy of M. farcinogenese and M. senegalense 11. 1.3. Immunology of bovine farcy agents. 36. CHAPTER TWO. MATERIALS AND METHODOLOGY 41. Isolation, identification and characterization of M. farcinogenes. 2.1 Phenotypic characterization. 41. 2.1.1. Morphological and biochemical tests. 2.1.2. Degradation tests. 2.1.3. Rapid fluorogenic enzyme tests. 2.1.4. Nutritional tests. 2.1.5. Physiological tests. 2.2. Molecular characterization. 52. 2.2.1. DNA extraction and purification 2.2.2. PCR amplification and application. 2.2.3. DNA sequencing of 16SrDNA. 2.2.4. PCR-based restriction fragment length polymorphism. 2.3 Imrmmological analyses of bovine farcy agents. 71. 2.3.1 .EL1SA technique for sera diagnosis. 2.3.2 Animal pathogenicity Tests. 2.3.3 Protein antigen profiles determination using. CHAPTER THREE: RESULTS. 78. CHAPTER. FOUR: DISCUSSION. 124. REFERENCES. 133.
    [Show full text]